Introduction: POEMS syndrome is a rare paraneoplastic syndrome caused by an underlying plasma cell disorder. The acronym refers to the following features: polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal paraproteinemia, and skin changes. Methods: The study was conducted at 24 hematological centers across 8 Latin-American countries. The study included a total of 46 patients {median age was 52 years (interquartile range [IQR]: 42–61.5), 30 males and 16 females} fulfilling the POEMS syndrome criteria diagnosed over a period of 12 years (January 1, 2011, through July 31, 2023). Epidemiological and clinical data were collected in an ad hoc database sent to the members of GELAMM, as well as the Kolmogorov-Smirnov test and Kaplan-Meier estimates. Results: All patients had polyneuropathy and monoclonal gammopathy; 89% had bone marrow plasma cell infiltration, 33% had sclerotic bone lesions. Only 10 patients underwent vascular endothelial growth factor (VEGF) testing in plasma samples. The paraproteinemia was IgG λ in 32% and IgA λ in 30%. 59% patients presented with cutaneous changes, mainly hyperpigmentation, 54% had organomegaly, and 74% endocrinopathy. The median interval from symptom onset to diagnosis was 7.7 months (IQR: 4.0–12.6). 69% of patients received a single line of treatment. The median follow-up period was 25 months (IQR: 9.37–52.0) and the 2-year overall survival rate was 100%. All patients who underwent transplantation (43%) are alive, with a median follow-up of 45.62 months (IQR: 15.46–70). Conclusion: This study investigates POEMS syndrome in Latin America and presents an initial overview of the disease in the region. VEGF usage is recommended for accurate diagnosis, but only 7 hematology centers in the region used it. Survival rate in Latin America is comparable with those observed internationally.

1.
Lee-Chen
L
,
Williams-De-roux
R
,
Chiquete
E
,
Aceves-Buendía
JJ
,
Ruiz-Ruiz
E
,
Portillo-Valle
J
, et al
.
Clinical and neurophysiological description of patients with poems syndrome
.
Gac Med Mex
.
2021
;
157
(
5
):
466
72
.
2.
Dispenzieri
A
,
Morra
E
,
Weber
D
.
POEMS syndrome plasma cell disorders: atypical plasma cell syndromes
.
American Society of Hematology [Internet]
.
2005
;
360
7
. Available from: http://ashpublications.org/hematology/article-pdf/2005/1/360/645214/360.pdf
3.
Zhao
H
,
Huang
XF
,
Gao
XM
,
Cai
H
,
Zhang
L
,
Feng
J
, et al
.
What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone
.
Leukemia
.
2019
;
33
(
4
):
1023
9
.
4.
D’Souza
A
,
Lacy
M
,
Gertz
M
,
Kumar
S
,
Buadi
F
,
Hayman
S
, et al
.
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
.
Blood
.
2012
;
120
(
1
):
56
62
.
5.
Suichi
T
,
Misawa
S
,
Beppu
M
,
Takahashi
S
,
Sekiguchi
Y
,
Shibuya
K
, et al
.
Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese Nationwide survey
.
Neurology
.
2019
;
93
(
10
):
E975
83
.
6.
Wang
C
,
Huang
XF
,
Cai
QQ
,
Cao
XX
,
Duan
MH
,
Cai
H
, et al
.
Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome
.
Leukemia
.
2017
;
31
(
1
):
100
6
.
7.
Li
J
,
Huang
XF
,
Cai
QQ
,
Wang
C
,
Cai
H
,
Zhao
H
, et al
.
A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome
.
Am J Hematol
.
2018
;
93
(
6
):
803
9
.
8.
Kanai
K
,
Sawai
S
,
Sogawa
K
,
Mori
M
,
Misawa
S
,
Shibuya
K
, et al
.
Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome
.
Neurology
.
2012
;
79
(
6
):
575
82
.
9.
Misawa
S
,
Sato
Y
,
Katayama
K
,
Hanaoka
H
,
Sawai
S
,
Beppu
M
, et al
.
Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study
.
BMJ Open
.
2015
;
5
(
11
):
e009157
7
.
10.
Dispenzieri
A
.
POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management
.
Am J Hematol
.
2021
;
96
(
7
):
872
88
.
11.
Shi
X
,
Hu
S
,
Yu
X
,
Zhuang
Q
,
Luo
M
,
Jiang
Q
, et al
.
Clinicopathologic analysis of POEMS syndrome and related diseases
.
Clin Lymphoma Myeloma Leuk
.
2015
;
15
(
1
):
e15
21
.
12.
Brown
R
,
Ginsberg
L
.
POEMS syndrome: clinical update
.
J Neurol
.
2019
;
266
(
1
):
268
77
.
13.
Morizane
R
,
Sasamura
H
,
Minakuchi
H
,
Takae
Y
,
Kikuchi
H
,
Yoshiya
N
, et al
.
A case of atypical POEMS syndrome without polyneuropathy
.
Eur J Haematol
.
2008
;
80
(
5
):
452
5
.
14.
Dispenzieri
A
.
POEMS syndrome: update on diagnosis, risk-stratification, and management
.
Am J Hematol
.
2023
;
98
(
12
):
1934
50
.
15.
Suichi
T
,
Misawa
S
,
Sato
Y
,
Beppu
M
,
Sakaida
E
,
Sekiguchi
Y
, et al
.
Proposal of new clinical diagnostic criteria for POEMS syndrome
.
J Neurol Neurosurg Psychiatry
.
2019
;
90
(
2
):
133
7
.
16.
Miest
RYN
,
Comfere
NI
,
Dispenzieri
A
,
Lohse
CM
,
El-Azhary
RA
.
Cutaneous manifestations in patients with POEMS syndrome
.
Int J Dermatol
.
2013
;
52
(
11
):
1349
56
.
17.
Caimari
F
,
Keddie
S
,
Lunn
MP
,
D’Sa
S
,
Baldeweg
SE
.
Prevalence and course of endocrinopathy in POEMS syndrome
.
J Clin Endocrinol Metab
.
2019
;
104
(
6
):
2140
6
.
18.
Gandhi
GY
,
Basu
R
,
Dispenzieri
A
,
Basu
A
,
Montori
VM
,
Brennan
MD
.
Endocrinopathy in POEMS syndrome: the mayo clinic experience
.
Mayo Clin Proc
.
2007
;
82
(
7
):
836
42
.
19.
He
T
,
Zhao
A
,
Zhao
H
,
Cai
H
,
Feng
J
,
Zhang
L
, et al
.
Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy
.
Ann Hematol
.
2019
;
98
(
3
):
735
43
.
20.
Oyenuga
M
,
Mohamed
MMG
,
Patel
R
,
Sartaj
S
,
Sen
S
,
Lacasse
A
, et al
.
POEMS syndrome: a diagnostic dilemma with challenging presentation
.
J Community Hosp Intern Med Perspect
.
2022
;
12
(
6
):
69
72
.
21.
D’Sa
S
,
Khwaja
J
,
Keddie
S
,
Keh
RYS
,
Smyth
D
,
Ronneberger
R
, et al
.
Comprehensive diagnosis and management of POEMS syndrome
.
Hemasphere
.
2022
;
6
(
11
):
E796
.
22.
Robey
RC
,
Campus
C
,
Ringuette
B
,
Shumate
M
.
POEMS syndrome: complex factors contributing to a delayed diagnosis
.
BMJ Case Rep
.
2015
;
2015
:
bcr2015213123
5
.
23.
Warsame
R
,
Yanamandra
U
,
Kapoor
P
.
POEMS syndrome: an enigma
.
Curr Hematol Malig Rep
.
2017
;
12
(
2
):
85
95
.
24.
Querol
L
,
Crabtree
M
,
Herepath
M
,
Priedane
E
,
Viejo Viejo
I
,
Agush
S
, et al
.
Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)
.
J Neurol
.
2021
;
268
(
10
):
3706
16
.
25.
Cerri
F
,
Falzone
YM
,
Riva
N
,
Quattrini
A
.
An update on the diagnosis and management of the polyneuropathy of POEMS syndrome
.
J Neurol
.
2019
;
266
(
1
):
258
67
.
26.
Kuwabara
S
,
Suichi
T
,
Misawa
S
.
Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs by Marsh et al
.
J Neurol Neurosurg Psychiatry
.
2021
;
92
(
2
):
118
9
.
27.
Marsh
ES
,
Keddie
S
,
Terris-Prestholt
F
,
D’Sa
S
,
Lunn
MP
.
Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs
.
J Neurol Neurosurg Psychiatry
.
2021
;
92
(
2
):
172
6
.
28.
Kaygusuz
I
,
Tezcan
H
,
Cetiner
M
,
Kocakaya
O
,
Uzay
A
,
Bayik
M
.
Bortezomib: a new therapeutic option for POEMS syndrome
.
Eur J Haematol
.
2010
;
84
(
2
):
175
7
.
29.
Fu
LY
,
Zhang
HB
.
Effective treatment of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome with congestive heart failure: a case report
.
World J Clin Cases
.
2021
;
9
(
25
):
7504
11
.
30.
Ishii
Y
,
Yamazaki
E
,
Ishiyama
Y
,
Yamamoto
E
,
Hattori
Y
,
Hagihara
M
, et al
.
Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation
.
Int J Hematol
.
2013
;
98
(
6
):
723
8
.
31.
Gao
XM
,
Yu
YY
,
Zhao
H
,
Cai
H
,
Zhang
L
,
Cao
XX
, et al
.
Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome
.
Ann Hematol
.
2021
;
100
(
11
):
2755
61
.
You do not currently have access to this content.